Giner Life Sciences News
Giner Life Sciences Awarded a Phase I Grant
Giner Life Sciences has been awarded a Phase I Grant from the National Institute of Deafness and Other Communication Disorders (NIDCD) to improve the outcome of middle ear surgeries. This work will fund the adaptation of Giner’s proven miniature Electrochemical Oxygen Generator (EOG) technology to produce a wearable Ear Oxygenation Device (wEOD) for use after middle ear surgeries. Current failure rates for the estimated 210K middle ear surgeries performed each year in the US alone range up to 26%.
Distinguished collaborators Dr. Elizabeth Toh, a specialist in Otolaryngology/Ear, Nose and Throat at the Lahey Clinic; and Dr. Peter Weber, Otolaryngologist and Professor at the BU School, and affiliated with the Ear Infirmary of Mount Sinai; will act as the program’s otolaryngologist consultants. Both believe that delivery of concentrated oxygen to the wound site, post-surgery, will prevent revision surgeries by drying the middle ear sooner and reducing the recovery period.
“I am honored to have the opportunity to work with the NIDCD and Drs. Toh and Weber on improving surgical outcomes,” said Melissa Schwenk, the Giner Life Sciences' Engineer who is the Principal Investigator for the project. “Our objective of improving the recovery time and preventing follow-up surgeries aligns well with the NIDCD mission of supporting research related to disease prevention and health promotion. The wEOD presents a real opportunity to directly improve patients’ lives.”
“This award illustrates the versatility of the Giner Life Sciences technology platform”, said Dr. Linda Tempelman, the CEO of Giner Life Sciences. “Our innovative miniature implantable and wearable oxygen generators, hydrogen generators and cell capsules are a game changing platform not just for cell therapies, but also for a wide variety of other medical devices, surgical interventions and treatments.”